In this article:

Maxim Group Thinks Clene’s Stock is Going to Recover

In this article:
In this article:

Maxim Group analyst Naz Rahman maintained a Buy rating on Clene (CLNNResearch Report) on February 2 and set a price target of $9.00. The company’s shares closed last Friday at $2.84, close to its 52-week low of $2.36.

According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals.

The the analyst consensus on Clene is currently a Moderate Buy rating.

See the top stocks recommended by analysts >>

Clene’s market cap is currently $177M and has a P/E ratio of -3.23.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLNN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tottenham Acquisition I Ltd. is a blank check company. Its purpose is to acquire, engage in a share exchange, share reconstruct, amalgate, and purchase all substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities. The company was founded on November 13, 2017 and is headquartered Hong Kong.

Read More on CLNN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed